March 2022 - Page 3 of 4 - PsychedelicNewsWire (PNW)

WednesdayMar 16, 2022 9:00 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Leverages Research to Promote Mental Health

Delic Holdings Corp, a leader in new medicines and treatments for a modern world, understands that research is integral for both the rapidly developing psychedelics and cannabis industries, and for psychedelics to be widely adopted for the treatment of mental health issues Dr. Markus Roggen, President and CSO of Delic Labs, recently spoke at this year’s Emerald Conference, and has reiterated the importance of leveraging AI in crafting products for the cannabis industry Delic is continually expanding its efforts to conduct and encourage even more research and education in support of high-quality products for more people, supporting mental health while…

TuesdayMar 15, 2022 1:56 pm

Giving Zebrafish Microdoses of LSD Reveals Therapeutic Potential

Zebrafish share about 70% of the same genes with humans and roughly 85% of human genes known to be linked to human diseases. This makes them a unique model animal for biomedical research, in addition to being social, which makes them suitable for behavioral research into drug discovery and psychiatric disorders. Researchers conducting studies on LSD are microdosing zebrafish in an effort to explore potential new treatments for alcohol use disorder and mental illness. Microdosing refers to ingesting small amounts of a psychedelic. It is believed that microdosing improves open-mindedness, sparks creativity and increases productivity. For their study, the researchers…

MondayMar 14, 2022 11:24 am

Missouri Legislator Files Measure to Decriminalize Psychedelics

Last week, a Missouri legislator filed a measure that would legalize an extensive range of psychedelic drugs for therapeutic use and decriminalize low-level possession in the state. The measure was sponsored by Republican lawmaker, Rep. Tony Lovasco. It is the latest example of psychedelic reforms being introduced in states that are traditionally conservative. The measure would provide patients suffering from conditions such as post-traumatic stress disorder treatment-resistant depression and other terminal illnesses with access to a wider range of substances including ibogaine, mescaline, DMT and psilocybin in a clinical setting. Patients will be allowed to access this treatment option at…

FridayMar 11, 2022 2:06 pm

Research Finds That Psilocybin Mushrooms May Help Treat Severe Depression

Psilocybin has been used for millennia around the globe for many uses, including for spiritual connections as well as a remedy in some Indigenous communities. Research has shown that this hallucinogenic compound found in “magic mushrooms” can be used to treat severe depression. However, since it was banned in 1970, psilocybin remains classified as a Schedule I substance under the Controlled Substances Act. Substances under this classification are considered to have a high potential for abuse with no accepted medical use. This isn’t the case for most substances under this classification, and as more research on psychedelics surfaces, this may…

FridayMar 11, 2022 10:00 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Reports Positive Pre-IND Meeting with FDA, Changes to Its Clinical Trial Approach; Plans Breakthrough Therapy Designation Request for MYCO-001

Mydecine recently reported a positive Pre-IND meeting with the FDA for the MYCO-001 smoking cessation study According to the Center for Disease Control (“CDC”), tobacco is the leading cause of preventable deaths in the U.S. Following the FDA meeting, the company now intends to perform a Phase 2b study and then a Phase 3 study instead of a seamless Phase 2/3 clinical trial Mydecine plans to submit a request for breakthrough therapy status with its IND submission Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) has continually taken steps toward fulfilling its mission to become a trusted source of safe and…

ThursdayMar 10, 2022 12:07 pm

Psychedelics May Help Individuals with Eating Disorders

Negative body image usually causes anxiety and depression, and in most people, it can also cause eating disorders and body dysmorphia to develop. Figures from the National Association of Anorexia Nervosa and Associated Disorders show that about 9% of the global population suffers from eating disorders. These conditions mainly affect women, many of whom have shared how psychedelics have helped them manage body dysmorphia, dissatisfaction and the stress, depression and anxiety that accompanies this cycle. Body dysmorphia is a psychological disorder that causes an individual to imagine imperfections or overvalue minute imperfections by being excessively concerned with their bodies. While…

WednesdayMar 09, 2022 1:17 pm

Colorado May Soon Decriminalize Psilocybin Mushrooms

Psychedelics were made illegal when the Controlled Substances Act of 1970 was enacted, with most of the substances being classified as Schedule I. Substances under this category are considered to have a high potential for abuse with no current accepted medical use. However, recent studies have shown that naturally derived psychedelics, including DMT, ibogaine and mescaline, which have been used by various communities for hundreds of years, possess the potential to heal a number of indications. These clinical trials and studies have shown that psychedelics such as psilocybin have the potential to treat post-traumatic stress disorder, end-of-life anxiety and severe…

TuesdayMar 08, 2022 3:18 pm

Dr. Bronner’s to Provide Employees with Ketamine-Assisted Therapy

In a recent press release, Dr. Bronner’s revealed that it had broadened its mental healthcare coverage as the first step in its strategy to provide access to psychedelic-assisted therapy to its employees as a means to promote mental health. This plan, which includes the use of ketamine in combination with therapy, is to be administered by Enthea, a not-for-profit healthcare organization that is responsible for benefit plan administration, provider network management and medical policy development. The organization also establishes quality-of-care standards for provided treatments, including the management of a specialty provider network. Dr. Bronner’s is collaborating with Enthea because both…

MondayMar 07, 2022 12:13 pm

Signs the Psychedelics Renaissance Is Here to Stay

It seems psychedelics are here to stay, what with the developments being seen in different parts of the country. These natural substances were being used by Indigenous communities way before the West began to embrace the use of drugs such as LSD in the ‘50s. During this period before the drugs were banned in 1970, significant research looking into psychedelic-assisted therapy was conducted, with numerous studies showing their potential in the treatment of addiction, anxiety and depression. Recently, we’ve seen psychedelics go mainstream again, thanks to new clinical trials and studies that have convinced regulatory bodies, including the U.S. FDA…

MondayMar 07, 2022 11:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), Chopra Foundation Partner in Efforts to Support Progress Toward Psychedelic-Based Therapeutics

Psychedelic drugs are on cusp of entering mainstream treatment for mental illness Cybin, Chopra Foundation to collaborate on efforts aimed to support education, awareness about psychedelic therapy mental health research Cybin “one of the only companies that may truly address the needs of patients and providers,” says Dr. Deepak Chopra A significant increase in research and growing public support are key indicators of the future of psychedelics, which are “on the cusp of entering mainstream psychiatry,” according to a recent “New York Times” article (https://ibn.fm/GshwS). Another strong indicator of the future of psychedelics is the exciting partnership just announced by…

News and publishing service for psychedelic related companies

Contact us: 415.949.5050

Month: March 2022